Drugmaker Alkem Laboratories said it expects its domestic formulation segment to do well in Q1FY22 led by growth momentum in the acute component, more specifically its anti-infective division.
The company says it is seeing a huge demand for anti-infectives like antibiotics in the COVID-19 second wave.
"In 2020 COVID-19, the secondary infection of pneumonia wasn't there, which is extremely high this year, the main reason why antibiotics have shown very good revival; and of course allied therapies like acidity management, Vitamin-C and zinc preparations have shown good growth," said Sandeep Singh, Managing Director of Alkem Laboratories at the compamy's earnings call on May 25.
"Q1FY22 should do much better than Q1FY21 of last year," he predicted.
Alkem said it expects its India business to grow at `mid-teen’ levels in FY22.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
The company derives 80 percent of its revenues from the domestic formulation business through the acute segment, of which anti-infectives alone contribute about 40 percent.
In the first wave, sales of antibiotics had collapsed due to lockdowns and COVID-19 appropriate behaviour, which reduced the infections.
But in the COVID-19 second wave, secondary infections due to bacteria and fungus have gained traction. Doctors are using antibiotics much more aggressively in COVID-19 patients to keep these infections, especially pneumonia, at bay.
Alkem earned Rs 8,865 crore as revenues from operations in FY21, registering a year-on-year (YoY) growth of 6.2 percent. Its India sales stood at Rs 5,699.6 crore, which accounts for 64 percent of total revenues. The sales grew YoY at 4.5 percent.
International sales, which account for the rest, were pegged at Rs 3,028.8 crore. It rose 10.6 percent YoY.
Alkem expects the anti-infective segment to do well in FY22, compared to the low base of last year.
Noted Motilal Oswal in its latest report: "Healthy momentum in chronic therapies and increased usage of vitamins/minerals/nutrients and pain products should enable ALKEM to deliver 13.5 percent sales CAGR (Compound Annual Growth Rate) over FY21-23E.""It plans to launch more products in the US in FY22 than it did in FY21. This, along with a ramp up in existing products, should enable faster growth in FY22," the report added.